NCT00960791

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)

An Open, Single-centre, Single Group, Phase I Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of AZD1656 After Oral Administration of 14C-labelled AZD1656 to Type II Diabetes Mellitus Patients

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: Male
• Age: 35 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the absorption, distribution, metabolism and excretion of AZD1656 after administration of a single oral dose of 14C-labelled AZD1656 solution in male Type 2 Diabetes Mellitus patients.

Conditions

• Type II Diabetes Mellitus

Interventions

Type	Name	Description
DEVICE	AZD1656	Oral single dose

Timeline

• Start date: 2009-07-01
• Completion: 2009-09-01
• First posted: 2009-08-18
• Last updated: 2009-09-16

Locations

2 sites across 1 country: United States